HM71224

Poseltinib

Poseltinib

Chemical compound

Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly.[1]

Quick Facts Clinical data, Other names ...

Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.[2]

References

  1. [1]
    Alternative Names: HM 71224; LY 3337641. "Poseltinib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.{{cite web}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
  2. [2]
    "Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy (NYSE:LLY)". Investor.lilly.com. 2015-03-19. Retrieved 2017-05-22.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article HM71224, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.